An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia

Trial Profile

An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Evinacumab (Primary) ; Evinacumab (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 30 Oct 2017 Planned End Date changed from 1 Dec 2020 to 16 Mar 2018.
    • 30 Aug 2017 Results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 03 Aug 2017 Primary endpoint has been met (Percent change in low-density lipoprotein cholesterol (LDL-C) from baseline (week 0) to week 4.), according to a Regeneron Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top